Status:
RECRUITING
A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Lead Sponsor:
Kumquat Biosciences Inc.
Conditions:
Solid Tumor Malignancies
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The goal of this clinical trial is to learn if KQB168 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB168. The main questions it aims to answer are: * ...
Eligibility Criteria
Inclusion
- Histologically confirmed diagnosis of solid tumor malignancy.
- Unresectable or metastatic disease that has progressed on immunotherapy.
- No available treatment with curative intent
- Adequate organ function
- Measurable disease per RECIST v1.1
Exclusion
- Active primary central nervous system tumors
- Cardiac abnormalities
- History of lung diseases
- Any condition that may impair drug absorption or prevent oral dosing
- Known history of immune-mediated colitis and uncontrolled autoimmune diseases
Key Trial Info
Start Date :
June 24 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 31 2028
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT06994806
Start Date
June 24 2025
End Date
May 31 2028
Last Update
July 11 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
NEXT Austin
Austin, Texas, United States, 78758
2
NEXT Huston
Houston, Texas, United States, 77054
3
NEXT Oncology
San Antonio, Texas, United States, 78229
4
NEXT Virginia
Fairfax, Virginia, United States, 22031